<DOC>
	<DOCNO>NCT01405326</DOCNO>
	<brief_summary>The purpose study ass whether 6-month treatment adalimumab add treatment conventional antirheumatic drug ( DMARD ) decrease number day sick leave compare placebo . In addition , cost-effectiveness cost-utility intervention compare conventional treatment evaluate , patient benefit characterize .</brief_summary>
	<brief_title>REstore Working Ability RheumatoiD Arthritis</brief_title>
	<detailed_description>In spite improved medical treatment , rheumatoid arthritis ( RA ) still cause significant morbidity mark loss work productivity . Short period work inability , i.e. , sick leaf represent significant part socioeconomic burden RA . The study randomize , control double blind multi-center study . 160 patient 25 55 year age recent-onset ( ≤2 year diagnosis ) RA treat combination conventional antirheumatic drug inadequate response treatment risk lose ability work , enrol . The patient biologic-naïve . Their RA active , active conventional criterion biologic therapy would fulfil . The subject randomize 1:1 ratio receive either adalimumab ( 40 mg every two week ) placebo 6 month add concurrent antirheumatic therapy . The RA-related sickness absence clinical response evaluate .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Diagnosis RA accord 1987 revised American College Rheumatology ( ACR ) criteria 2 . Time diagnosis RA &lt; 2 year 3 . Age 2555 year 4 . Active RA least 3 active joint ( tender and/or swollen joint ) 5 . Stable DMARD combination treatment 3 month 6 . At least one follow Rheumatoid factor positive One erosion xrays hand foot Anticitrulline antibody positive 7 . At least follow HAQindex 0.5 Patient physician evaluation RA activity &gt; 25 mm ( VAS 010 cm ) 8 . Patient steadily worklife least one year currently work sick leave apply pension 9 . Patient feel he/she likely offwork follow 6 month due his/her RA 10 . Patient must willing able provide write informed consent trial 11 . Each female subject must agree use medically accept method contraception receive study medication 1 . A subject must history biological drug use RA 2 . A subject must evidence active latent tuberculosis , 3 . A subject must history lymphoproliferative disease malignancy within previous 5 year 4 . A subject must condition , accord investigator 's judgment make noneligible antiTNF use 5 . A subject must inflammatory rheumatic disease RA 6 . A subject must receive investigational agent within 30 day prior baseline visit , must receive current trial 7 . A female subject must pregnant breastfeed plan pregnancy study 8 . A subject must major surgery within one month prior study entry must schedule operation 6month follow 9 . A subject must clinically significant condition situation , condition study , opinion investigator would interfere optimal participation trial . 10 . A subject must fulfill criterion reimbursement biologics RA he/she would normally prescribe biological drug accord physician discretion national treatment guideline 11 . A patient must currently reimburse rehabilitation period , period must schedule next six month</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>biological therapy</keyword>
	<keyword>adalimumab</keyword>
	<keyword>ability work</keyword>
	<keyword>sick leaf</keyword>
</DOC>